The pooled sensitivity and specificity of RASSF1A methylation in our study was 0.49 and 0.95, respectively, which indicated that 49% of BC patients enjoyed high RASSF1A methylation levels, and 95% of non-breast-cancer patients had low RASSF1A methylation levels. Here, RASSF1 is linked to breast cancer.